2025-07-14

King-Friend will meet you in CPHI Malaysia！

Return

Previous NKF's subsidiary Kindos's Idarubicin Hydrochloride Injection gets FDA approval for marketing Next NKF makes its debut at CPHI Southeast Asia

Relevant recommendations

2025-08-04

NKF's subsidiary Kindos's Etoposide Injection gets FDA approval for marketing
2025-07-21

NKF makes its debut at CPHI Southeast Asia
2025-05-26

NKF's subsidiary Kindos's Idarubicin Hydrochloride Injection gets FDA approval for marketing
2025-05-22

NKF's subsidiary Kindos's Mitoxantrone Injection gets FDA approval for marketing
2025-05-20

Paclitaxel For Injection (Albumin Bound) approved by US FDA

Stock price

11.660

-0.039999999999999

©2025 Nanjing King-Friend Biochemical Pharmaceutical Co.Ltd苏ICP备13012010号